Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
Artificial intelligence has rapidly moved from a buzzword to a core component of modern drug development. From target identification and molecule design to clinical trial optimization, AI pr...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Canada’s biopharma sector is entering a defining phase where scientific ambition is increasingly intersecting with economic reality. Breakthroughs in gene therapies, precision medicine, and AI driven ...
The pharmaceutical industry has historically operated as one of the world’s most globally interconnected sectors, relying on international supply chains, cross border research collaboration, and multi...
Healthcare is undergoing a major cultural and commercial shift as patients become more informed, digitally connected, and actively involved in their care decisions. What was once a largely physician d...
